StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Nov 3, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Medrol [legacy through FY23] by Quarter

Medrol (methylprednisolone) [legacy through FY23] — Worldwide reported YoY (%) (%)

QuarterlyAnnual

Pfizer Medrol [legacy through FY23]: -18.0% in Q4 2023, down 1.0 pts from a year earlier. No newer figure appears in the documents we track.

Latest, Q4 2023
-18.0%
Period ended Dec 31, 2023
Change on a year earlier
-1.0 pts
-17.0% in Q4 2022
History
24 quarters
Since Q4 2017
Sources
24
Documents cited below

Where the Q4 2023 figure comes from

“|| Medrol | 76 | 93 | (18%) | (19%) | 21 | 43 | (51%) | 55 | 50 | 9% | 8%”

Source: Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗

Reported in Form 8-K Revenue Tables.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedMedrol (methylprednisolone) [legacy through FY23] — Worldwide reported YoY (%) (%)Year on yearSource
Q4 2023Dec 31, 2023-18.0%-1.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
Q3 2023Oct 1, 202312.0%+39.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-10012023xex99.htm, filed 2023-10-31) ↗
Q2 2023Jul 2, 20231.0%+31.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-07022023xex99.htm, filed 2023-08-01) ↗
Q1 2023Apr 2, 202322.0%+45.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-04022023xex99.htm, filed 2023-05-02) ↗
Q4 2022Dec 31, 2022-17.0%-21.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗
Q3 2022Oct 2, 2022-27.0%-52.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-10022022xex99.htm, filed 2022-11-01) ↗
Q2 2022Jul 3, 2022-30.0%-74.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-07032022xex99.htm, filed 2022-07-28) ↗
Q1 2022Apr 3, 2022-23.0%0.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-04032022xex99.htm, filed 2022-05-03) ↗
Q4 2021Dec 31, 20214.0%+11.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312021xex99.htm, filed 2022-02-08) ↗
Q3 2021Oct 3, 202125.0%+49.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-10032021xex99.htm, filed 2021-11-02) ↗
Q2 2021Jul 4, 202144.0%+79.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-07042021xex99.htm, filed 2021-07-28) ↗
Q1 2021Apr 4, 2021-23.0%-31.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-04042021xex99.htm, filed 2021-05-04) ↗
Q4 2020Dec 31, 2020-7.0%-4.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312020xex99.htm, filed 2021-02-02) ↗
Q3 2020Sep 27, 2020-24.0%-23.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-09272020xex99.htm, filed 2020-10-27) ↗
Q2 2020Jun 28, 2020-35.0%-33.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-06282020xex99.htm, filed 2020-07-28) ↗
Q1 2020Mar 29, 20208.0%+20.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-03292020xex99.htm, filed 2020-04-28) ↗

Cite this data

StockData. (2026). Pfizer Medrol [legacy through FY23] (%), quarterly Q4 2017–Q4 2023 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/medrol-leg-yoy-ww

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.